Cogent Biosciences, Inc. cash flow to debt ratio of -104.46% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cogent Biosciences, Inc.'s free cash flow has decreased 27.66% from $-208.36M last year to $-266.00M, signaling decreasing performance

Cogent Biosciences, Inc.'s debt to equity ratio is 0.46, which means that the company's assets are healthy financed, signaling financial stability.

Cogent Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.07 last year to 0.46 today, signaling weakened financials

Cogent Biosciences, Inc. has a net cash position, so leverage is healthy.

Cogent Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cogent Biosciences, Inc. has insufficient data to evaluate this check.

Cogent Biosciences, Inc.'s short-term assets of $910.36M exceed its short-term liabilities of $63.95M

Cogent Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cogent Biosciences, Inc.'s return on equity of -72.57%, is lower than 15.00%, indicating bad performance

Cogent Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cogent Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Cogent Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cogent Biosciences, Inc. has negative free cash flow, indicating cash burn

Cogent Biosciences, Inc.'s yearly earnings has decreased 28.56% since last year from $-255.86M to $-328.94M, signaling decreasing performance

Cogent Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -50.09% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cogent Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Cogent Biosciences, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Cogent Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Cogent Biosciences, Inc. has insufficient data to evaluate this check.

Cogent Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cogent Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cogent Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cogent Biosciences, Inc. has insufficient data to evaluate this check.

Cogent Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cogent Biosciences, Inc. has a price-to-book ratio of 13.34x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Cogent Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue